ArticleArquivos de neuro-psiquiatria2025

Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease.

Ricardo Nitrini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.